AscellaHealth Releases Q4 2024 Specialty & Rare Pipeline Digest™ Featuring Key Specialty Drug, Biosimilar, Cell and Gene Therapy Approvals
January 09, 2025 10:00 ET
|
AscellaHealth, LLC
AscellaHealth Releases Q4 2024 Specialty & Rare Pipeline Digest™ Featuring Key Specialty Drug, Biosimilar, Cell and Gene Therapy Approvals
AscellaHealth Ranked Number 154 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
November 21, 2024 10:03 ET
|
AscellaHealth, LLC
2024 Deloitte Technology Fast 500™ Ranks AscellaHealth Number 154 with 753% Revenue Growth